title: [Is it possible to reduce the number of patients studied in drug tests before the drug tested is authorized for marketing?].
authors.affiliation: Spriet Consultant, Paris.
authors.forename: R
authors.initials: R
authors.lastname: Flamant
authors.forename: A
authors.initials: A
authors.lastname: Spriet
authors.forename: C
authors.initials: C
authors.lastname: Caulin
authors.forename: F
authors.initials: F
authors.lastname: Doyon
authors.forename: J L
authors.initials: JL
authors.lastname: Cazor
authors.forename: P
authors.initials: P
authors.lastname: Jaillon
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D017327:Clinical Trials, Phase IV as Topic; D017277:Drug Approval; D005602:France; D006801:Humans; D007880:Legislation, Drug; D010361:Patients; D014481:United States; D014486:United States Food and Drug Administration
vernacular_title: Peut-on diminuer le nombre de patients étudiés avant Autorisation de Mise sur le Marché?